Gentel® Obtains License from Agnitio for Protein Microarray Technology
News Aug 13, 2008
Gentel® Biosciences has announced that it has obtained an exclusive license to novel technology for manufacturing highly-reproducible nitrocellulose protein microarray slides.
The technology, developed by Agnitio Science and Technology of Hsinchu, Taiwan, covers the use of ultrasonic coating to produce nitrocellulose films. “Ultrasonic coating produces nitrocellulose films with a consistency unattainable using traditional coating processes like casting,” stated Dr. Bryce Nelson, Gentel’s VP of Research and Development. “Additionally, the technology is extremely flexible and can be used to fabricate optically clear or porous white nitrocellulose films.”
Gentel plans to incorporate ultrasonic coating technology into its manufacturing process for standard microarray slides as well as for its recently developed 96-well microarray platform, APiX 96™.
“The technology is highly scalable and will enable us to manufacture the number and type of protein microarray slides required for protein biomarker discovery, validation, and diagnostics,” says G. Randall Durnell, Gentel VP of Commercial Operations. “The acquisition of this intellectual property further extends Gentel’s position as the market leading protein microarray company.”
The ultrasonic coating technology is covered by a suite of issued and pending US and international patents.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE